ANP32B and breast carcinoma: ANP32A was shown to inhibit cell transformation15, 16, 17 and has reduced expression in prostate and breast cancer.18, 19ANP32E was reported to have enhanced expression in gastric cancer,20 and a high expression of ANP32E was associated with better survival rate in follicular lymphoma.21 Previously we reported that ANP32B, also designated as PHAPI2 or SSP29, is a negative prognostic indicator for human breast cancer.22 Full analysis of the expression and functional role of ANP32B in cancer progression has still not been undertaken.